PMED impairment technology reports high accuracy ratesToday’s news:
https://www.accesswire.com/683025/Predictmedix-Announces-Accuracy-Rates-for-Alcohol-and-Cannabis-Impairment-Detection-Technology-and-Provides-Update-on-the-Next-Steps-for-Technology-Commercialization is a game changer for the company (
www.Predictmedix.com ) (CSE:PMED) (OTCQB:PMEDF) and the cannabis industry!
Employers are extremely concerned about workplace impairment and resulting injuries and accidents due to alcohol and drug use. They are also under a legal obligation to ensure the health and safety of all employees (and guests and customers) at work but current testing methods (using blood, breath, urine, hair samples, spit) are invasive, do not report results in real-time (i.e.. takes several minutes or worst case you have to send to a lab for analysis), costly, or not appropriate for the situation. As well, in the case of cannabis-induced impairment it is well known from many published studies that blood and oral fluid THC concentrations are relatively poor or inconsistent indicators of cannabis-induced impairment. Organizations are facing an immense problem especially now that cannabis use is legal in many jurisdictions around the world.
Predictmedix’s impairment detection solution solves these problems with their Safe Entry Station that is accurate, contactless, easy to use, cost-effective, and provides immediate results for both cannabis and alcohol presence.
To demonstrate the possible huge upside here, one of their competitors, Cannabix Technologies (CSE: BLO) (OTCQB BLOZF), trades with 5x the market cap, has zero (0) sales revenue, a breathalyzer device that is in the advanced prototype stage with only two beta (testing) sites and is only for cannabis (not alcohol) screening.